ArticleOPEN ACCESS

The future of kinase inhibitors for DLBCL?

Blood
DOI: 10.1182/blood-2018-04-841908
4Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Battistello et al present results exploring inhibition of signaling across key nodes in the B-cell receptor (BCR) signaling pathway for Bruton tyrosine kinase (BTK)-sensitive and BTK-insensitive diffuse large B-cell lymphoma (DLBCL).

Cite

CITATION STYLE

APA

Herman, S. E. M. (2018, May 24). The future of kinase inhibitors for DLBCL? Blood. American Society of Hematology. https://doi.org/10.1182/blood-2018-04-841908

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free